Elena Ricart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elena Ricart has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Ingrid Ordás
IBD Unit Hospital Clínic Barcelona Barcelona Spain
15 shared publications Julian Panes
11 shared publications- Jordi Rimola
University of Barcelona; Hospital Clinic; Villaroel 170 Barcelona Spain 08036
7 shared publications - Maria Pellisé
Gastroenterology Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain
6 shared publications - Montserrat Aceituno
Hospital Universitari Mútua Terrassa, 08221 Terrassa, Spain
6 shared publications Orlando García-Bosch
6 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
437 - Development and Validation of a Simplified Magnetic Resonance Index of Activity (Smaria) for Crohn's Disease
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
437 - Development and Validation of a Simplified Magnetic Resonance Index of Activity (Smaria) for Crohn's Disease
- Open Access
- 13 April 2017
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 11 (10) , 1161-1168
Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn’s Disease: Efficacy in a Single-Centre Cohort
Haematopoietic stem cell transplantation [HSCT] is considered a therapeutic option for patients with severe Crohn’s disease [CD] unresponsive to currently available therapies. Autologous HSCT was considered for CD patients with active disease, unresponsive or intolerant to approved medications and unsuitable for surgery. After HSCT, patients were closely followed up every 6 weeks during the first 2 years and every 6 months thereafter up to 5 years. Colonoscopy and/or magnetic resonance imaging were performed at Months 6, 12, 24, and 48 after HSCT. From December 1, 2007 to December 31, 2015, 37 CD patients were assessed for HSCT. Of these, 35 patients [13 within the ASTIC trial] underwent mobilisation. Six patients did not complete the transplant for various reasons and 29 patients were finally transplanted. Patients were followed up during a median of 12 months [6–60]. At 6 months, 70% of patients achieved drug-free clinical remission (Crohn’s Disease Index of Severity [CDAI] < 150). The proportion of patients in drug-free remission (CDAI < 150, Simple Endoscopic activity Score [SES]-CD < 7] was 61% at 1 year, 52% at 2 years, 47% at 3 years, 39% at 4 years, and 15% at 5 years. Patients who relapsed were re-treated and 80% regained clinical remission. Six out of the 29 [21%] required surgery. One patient died due to systemic cytomegalovirus infection 2 months after transplant. HSCT is a salvage therapy for patients with extensive and refractory CD. Although relapse occurs in a majority of patients within 5 years after transplant, drug responsiveness is regained and clinical remission achieved in 80% of cases.
- 13 April 2017
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 11 (10) , 1161-1168
Open AccessAutologous Haematopoietic Stem Cell Transplantation for Refractory Crohn’s Disease: Efficacy in a Single-Centre Cohort
Haematopoietic stem cell transplantation [HSCT] is considered a therapeutic option for patients with severe Crohn’s disease [CD] unresponsive to currently available therapies. Autologous HSCT was considered for CD patients with active disease, unresponsive or intolerant to approved medications and unsuitable for surgery. After HSCT, patients were closely followed up every 6 weeks during the first 2 years and every 6 months thereafter up to 5 years. Colonoscopy and/or magnetic resonance imaging were performed at Months 6, 12, 24, and 48 after HSCT. From December 1, 2007 to December 31, 2015, 37 CD patients were assessed for HSCT. Of these, 35 patients [13 within the ASTIC trial] underwent mobilisation. Six patients did not complete the transplant for various reasons and 29 patients were finally transplanted. Patients were followed up during a median of 12 months [6–60]. At 6 months, 70% of patients achieved drug-free clinical remission (Crohn’s Disease Index of Severity [CDAI] < 150). The proportion of patients in drug-free remission (CDAI < 150, Simple Endoscopic activity Score [SES]-CD < 7] was 61% at 1 year, 52% at 2 years, 47% at 3 years, 39% at 4 years, and 15% at 5 years. Patients who relapsed were re-treated and 80% regained clinical remission. Six out of the 29 [21%] required surgery. One patient died due to systemic cytomegalovirus infection 2 months after transplant. HSCT is a salvage therapy for patients with extensive and refractory CD. Although relapse occurs in a majority of patients within 5 years after transplant, drug responsiveness is regained and clinical remission achieved in 80% of cases.
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S385-S386
Endoscopic Response to Induction Therapy with TNF Inhibitors is the Best Predictor of Long Term Mucosal Healing in Crohn's Disease
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S385-S386
Endoscopic Response to Induction Therapy with TNF Inhibitors is the Best Predictor of Long Term Mucosal Healing in Crohn's Disease
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S613-S614
Resetting of the Mucosal T Cell Repertoire after Hematopoietic Stem Cell Transplantation in Refractory Crohn’s Disease
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S613-S614
Resetting of the Mucosal T Cell Repertoire after Hematopoietic Stem Cell Transplantation in Refractory Crohn’s Disease
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S390
Long-Term Outcomes of Anti-TNF Therapy Discontinuation in Patients with Penetrating Crohn's Disease
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S390
Long-Term Outcomes of Anti-TNF Therapy Discontinuation in Patients with Penetrating Crohn's Disease
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S203
991 Prediction of Clinical and Endoscopic Remission After Autologous Stem Cell Transplantation in Treatment Refractory Crohn's Disease: Pooled Results From the ASTIC Trial
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S203
991 Prediction of Clinical and Endoscopic Remission After Autologous Stem Cell Transplantation in Treatment Refractory Crohn's Disease: Pooled Results From the ASTIC Trial
- Open Access
- 1 March 2016
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 10 (9) , 1122-1124
Long-lasting Remission Induced by Syngeneic Haematopoietic Stem Cell Transplantation in a Patient with Refractory Crohn’s Disease
Autologous haematopoietic stem cell transplantation (HSCT) is considered a salvage therapy for patients with refractory immune-mediated diseases. Syngeneic HSCT may be an alternative to autologous HSCT, with potential advantages in terms of safety and efficacy. A patient with severe Crohn’s disease refractory to available medical therapies underwent a syngeneic HSCT from her identical twin sister. Cyclophosphamide and rabbit anti-thymocyte globulin were administered for conditioning. After transplant, the patient presented successful engraftment, complete haematological and immunological reconstitution, and no severe complications. The patient achieved complete remission after transplant which is sustained 4 years after transplantation without any active treatment for Crohn’s disease. Patients with refractory immune-mediated diseases who have an identical disease-free twin may benefit from a syngeneic HSCT.
- 1 March 2016
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 10 (9) , 1122-1124
Open AccessLong-lasting Remission Induced by Syngeneic Haematopoietic Stem Cell Transplantation in a Patient with Refractory Crohn’s Disease
Autologous haematopoietic stem cell transplantation (HSCT) is considered a salvage therapy for patients with refractory immune-mediated diseases. Syngeneic HSCT may be an alternative to autologous HSCT, with potential advantages in terms of safety and efficacy. A patient with severe Crohn’s disease refractory to available medical therapies underwent a syngeneic HSCT from her identical twin sister. Cyclophosphamide and rabbit anti-thymocyte globulin were administered for conditioning. After transplant, the patient presented successful engraftment, complete haematological and immunological reconstitution, and no severe complications. The patient achieved complete remission after transplant which is sustained 4 years after transplantation without any active treatment for Crohn’s disease. Patients with refractory immune-mediated diseases who have an identical disease-free twin may benefit from a syngeneic HSCT.
- 26 February 2016
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (7) , 2051-2059
Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response—An Observational Study
Aim To evaluate the early and long-term efficacy of infliximab in ulcerative colitis and to determine predictors of response and colectomy. Methods This is an ambidirectional cohort study in a tertiary referral center including patients who started infliximab within 2005 and 2008 and monitored until 2014. Efficacy was evaluated by partial Mayo scores at weeks 2, 4, 8, 30, and 54. Long-term treatment maintenance with infliximab and colectomy requirements were recorded. Results Fifty-three patients were included with a median follow-up of 69.5 months. Clinical remission at the time point assessments was 40.8, 47.2, 54.7, 54.7, and 49.1 %. At the time of maximal follow-up, the proportion of patients under infliximab maintenance was 24.5 %. A higher level of albumin (OR 1.4, CI 95 % 1.06–1.8; p = 0.017) was predictive of a higher remission rate at week 8. Concomitant immunomodulators beyond 6 months were predictive of infliximab’s long-term maintenance (OR 15.8, CI 95 % 1.8–135.4; p = 0.012). Colectomy was required in 41.5 %. Factors associated with a higher rate of colectomy at week 54 were previous treatment with cyclosporine (OR 3.4, CI 95 % 1.2–9.7; p = 0.012), absence of response at week 8 (OR 10.3, CI 95 % 3.3–31.7; p < 0.001), and not receiving concomitant immunomodulators (OR 4.1, CI 95 % 1.8–9; p = 0.002). Colectomy rates within the first 54 weeks were closely dependent on the number of variables present: none (0 %), 1 (26.3 %), 2 (71.4 %), or 3 (100 %) of them (log rank <0.0001). Conclusions Low albumin, previous treatment with cyclosporine, absence of a concomitant immunomodulator, and lack of response at week 8 negatively affected the efficacy of infliximab in ulcerative colitis.
- 26 February 2016
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (7) , 2051-2059
Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response—An Observational Study
Aim To evaluate the early and long-term efficacy of infliximab in ulcerative colitis and to determine predictors of response and colectomy. Methods This is an ambidirectional cohort study in a tertiary referral center including patients who started infliximab within 2005 and 2008 and monitored until 2014. Efficacy was evaluated by partial Mayo scores at weeks 2, 4, 8, 30, and 54. Long-term treatment maintenance with infliximab and colectomy requirements were recorded. Results Fifty-three patients were included with a median follow-up of 69.5 months. Clinical remission at the time point assessments was 40.8, 47.2, 54.7, 54.7, and 49.1 %. At the time of maximal follow-up, the proportion of patients under infliximab maintenance was 24.5 %. A higher level of albumin (OR 1.4, CI 95 % 1.06–1.8; p = 0.017) was predictive of a higher remission rate at week 8. Concomitant immunomodulators beyond 6 months were predictive of infliximab’s long-term maintenance (OR 15.8, CI 95 % 1.8–135.4; p = 0.012). Colectomy was required in 41.5 %. Factors associated with a higher rate of colectomy at week 54 were previous treatment with cyclosporine (OR 3.4, CI 95 % 1.2–9.7; p = 0.012), absence of response at week 8 (OR 10.3, CI 95 % 3.3–31.7; p < 0.001), and not receiving concomitant immunomodulators (OR 4.1, CI 95 % 1.8–9; p = 0.002). Colectomy rates within the first 54 weeks were closely dependent on the number of variables present: none (0 %), 1 (26.3 %), 2 (71.4 %), or 3 (100 %) of them (log rank <0.0001). Conclusions Low albumin, previous treatment with cyclosporine, absence of a concomitant immunomodulator, and lack of response at week 8 negatively affected the efficacy of infliximab in ulcerative colitis.
- 31 October 2013
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 14 (12) , 1453-1459
Cell Therapies for IBD: What Works?
Abstract: The inflammatory response in patients with inflammatory bowel disease is a complex self-amplifying process with multiple cellular and molecular pathways controlling activation and shut-off of the process. Available therapeutic interventions with drugs that have a very selective action, such as anti-tumor necrosis factor antibodies, or broader effects such as corticosteroids still leave a significant proportion of patients with Crohn’s disease and ulcerative colitis insufficiently treated. Cellular therapies are emerging as promising new approaches to treat inflammatory bowel diseases and in particular Crohn’s disease. Experimental and clinical data are the origin of the increasing utilization of cell therapies for severe immune-mediated diseases including inflammatory bowel disease. The types of cell therapies for these diseases can be divided into two different areas: hematopoietic stem cell therapies, and selected/conditioned immune cell therapy, the latter including mesenchymal stem cells and T-regulatory cells-based therapies.
- 31 October 2013
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 14 (12) , 1453-1459
Cell Therapies for IBD: What Works?
Abstract: The inflammatory response in patients with inflammatory bowel disease is a complex self-amplifying process with multiple cellular and molecular pathways controlling activation and shut-off of the process. Available therapeutic interventions with drugs that have a very selective action, such as anti-tumor necrosis factor antibodies, or broader effects such as corticosteroids still leave a significant proportion of patients with Crohn’s disease and ulcerative colitis insufficiently treated. Cellular therapies are emerging as promising new approaches to treat inflammatory bowel diseases and in particular Crohn’s disease. Experimental and clinical data are the origin of the increasing utilization of cell therapies for severe immune-mediated diseases including inflammatory bowel disease. The types of cell therapies for these diseases can be divided into two different areas: hematopoietic stem cell therapies, and selected/conditioned immune cell therapy, the latter including mesenchymal stem cells and T-regulatory cells-based therapies.